157 related articles for article (PubMed ID: 38287501)
1. Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study.
Yhim HY; Park Y; Kim JA; Shin HJ; Do YR; Moon JH; Kim MK; Lee WS; Kim DS; Lee MW; Choi YS; Jeong SH; Kim KH; Kim J; Lee CH; Song GY; Yang DH; Kwak JY
Korean J Intern Med; 2024 May; 39(3):501-512. PubMed ID: 38287501
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Geriatric Assessment (CGA): A Simple Tool for Guiding the Treatment of Older Adults with Diffuse Large B-Cell Lymphoma in China.
Bai JF; Han HX; Feng R; Li JT; Wang T; Zhang CL; Liu H
Oncologist; 2020 Aug; 25(8):e1202-e1208. PubMed ID: 32436258
[TBL] [Abstract][Full Text] [Related]
3. Development of a new clinical index to easily assess frailty of elderly patients with multiple myeloma in Asian population.
Lee HS; Lee J; Jo JC; Jung SH; Lee JJ; Kim D; Lee S; Song K
Sci Rep; 2021 Nov; 11(1):22907. PubMed ID: 34824362
[TBL] [Abstract][Full Text] [Related]
4. Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma.
Spina M; Balzarotti M; Uziel L; Ferreri AJ; Fratino L; Magagnoli M; Talamini R; Giacalone A; Ravaioli E; Chimienti E; Berretta M; Lleshi A; Santoro A; Tirelli U
Oncologist; 2012; 17(6):838-46. PubMed ID: 22610154
[TBL] [Abstract][Full Text] [Related]
5. Utility of the frailty score for predicting prognosis and individualizing treatment intensity in elderly patients with diffuse large B cell lymphoma.
Yagi Y; Kanemasa Y; Sasaki Y; Goto S; Yamamura Y; Ishimine K; Hayashi Y; Mino M; Ohigashi A; Morita Y; Tamura T; Nakamura S; Okuya T; Shimoyama T
Ann Hematol; 2023 Jun; 102(6):1485-1500. PubMed ID: 37115298
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B-cell lymphoma receiving rituximab-chemotherapy combinations.
Ong DM; Ashby M; Grigg A; Gard G; Ng ZY; Huang HE; Chong YS; Cheah CY; Devitt B; Chong G; Loh Z; Mo A; Hawkes EA
Br J Haematol; 2019 Oct; 187(1):73-81. PubMed ID: 31206608
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive geriatric assessment as a useful tool in predicting adverse events in elderly patients with diffuse large B-cell lymphoma.
Tanaka T; Sakai R; Choi I; Tsukada J; Sasaki H; Naito Y; Kiyomi F; Takamatsu Y; Tamura K
Sci Rep; 2022 Feb; 12(1):3124. PubMed ID: 35210509
[TBL] [Abstract][Full Text] [Related]
8. A Host-Dependent Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma.
Miura K; Konishi J; Miyake T; Makita M; Hojo A; Masaki Y; Uno M; Ozaki J; Yoshida C; Niiya D; Kitazume K; Maeda Y; Takizawa J; Sakai R; Yano T; Yamamoto K; Sunami K; Hiramatsu Y; Aoyama K; Tsujimura H; Murakami J; Hatta Y; Kanno M
Oncologist; 2017 May; 22(5):554-560. PubMed ID: 28408622
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and outcomes in diffuse large B cell lymphoma patients aged 70 years and older: a single-center experience with a literature review.
Jung YH; Woo IS; Han CW
Korean J Intern Med; 2015 Sep; 30(5):684-93. PubMed ID: 26354063
[TBL] [Abstract][Full Text] [Related]
10. Validation and Refinement of the Age, Comorbidities, and Albumin Index in Elderly Patients with Diffuse Large B-Cell Lymphoma: An Effective Tool for Comprehensive Geriatric Assessment.
Liu H; Zhang CL; Feng R; Li JT; Tian Y; Wang T
Oncologist; 2018 Jun; 23(6):722-729. PubMed ID: 29317552
[TBL] [Abstract][Full Text] [Related]
11. [Comprehensive geriatric assessment can predict the clinical outcomes of elderly patients with diffuse large B cell lymphoma in China].
Zhang CL; Feng R; Li JT; Tian Y; Wang T; Liu H
Zhonghua Xue Ye Xue Za Zhi; 2018 Apr; 39(4):271-276. PubMed ID: 29779319
[No Abstract] [Full Text] [Related]
12. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
Davies A; Cummin TE; Barrans S; Maishman T; Mamot C; Novak U; Caddy J; Stanton L; Kazmi-Stokes S; McMillan A; Fields P; Pocock C; Collins GP; Stephens R; Cucco F; Clipson A; Sha C; Tooze R; Care MA; Griffiths G; Du MQ; Westhead DR; Burton C; Johnson PWM
Lancet Oncol; 2019 May; 20(5):649-662. PubMed ID: 30948276
[TBL] [Abstract][Full Text] [Related]
13. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study.
Wieringa A; Boslooper K; Hoogendoorn M; Joosten P; Beerden T; Storm H; Kibbelaar RE; Veldhuis GJ; van Kamp H; van Rees B; Kluin-Nelemans HC; Veeger NJ; van Roon EN
Br J Haematol; 2014 May; 165(4):489-96. PubMed ID: 24754632
[TBL] [Abstract][Full Text] [Related]
14. A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL.
Isaksen KT; Mastroianni MA; Rinde M; Rusten LS; Barzenje DA; Ramslien LF; Slaaen M; Jerm MB; Smeland EB; Rostoft S; Liestøl K; Brodtkorb M; Holte H
Blood Adv; 2021 Nov; 5(22):4771-4782. PubMed ID: 34543384
[TBL] [Abstract][Full Text] [Related]
15. Impact of comorbidity and relative dose intensity on outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP.
Yamamoto M; Suzuki I; Saitou K; Tsumanuma R; Okuyama S; Kumagai H; Omoto E; Satoh S; Tajima K
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2995-3002. PubMed ID: 32524293
[TBL] [Abstract][Full Text] [Related]
16. Geriatric screening tools predict survival outcomes in older patients with diffuse large B cell lymphoma.
Sakurai M; Karigane D; Kasahara H; Tanigawa T; Ishida A; Murakami H; Kikuchi M; Kohashi S
Ann Hematol; 2019 Mar; 98(3):669-678. PubMed ID: 30443764
[TBL] [Abstract][Full Text] [Related]
17. Treatment Individualization in Diffuse Large B-Cell Lymphoma: Is Frailty Enough for Old Adults? An Original Article.
García-Baztán A; Oteiza-Olaso J; Gonzales-Montejo NJ; Ramón-Espinoza MF; Tamayo-Rodríguez I; Martínez-Velilla N; Viguria-Alegria MC
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):e348-e359. PubMed ID: 37487908
[TBL] [Abstract][Full Text] [Related]
18. Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the
Storti S; Spina M; Pesce EA; Salvi F; Merli M; Ruffini A; Cabras G; Chiappella A; Angelucci E; Fabbri A; Liberati AM; Tani M; Musuraca G; Molinari A; Petrilli MP; Palladino C; Ciancia R; Ferrario A; Gasbarrino C; Monaco F; Fraticelli V; De Vellis A; Merli F; Luminari S
Haematologica; 2018 Aug; 103(8):1345-1350. PubMed ID: 29748444
[TBL] [Abstract][Full Text] [Related]
19. Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma.
Lin RJ; Owens CN; Drill E; Iannotta A; Oliveros M; Schick DL; Noy A; Gerecitano JF; Drullinsky PR; Caron PC; Kumar A; Matasar MJ; Moskowitz C; Korc-Grodzicki B; Zelenetz AD; Salles GA; Hamlin PA
Haematologica; 2022 May; 107(5):1144-1152. PubMed ID: 34289656
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.
Djebbari F; Rampotas A; Panitsas F; Lim WY; Lees C; Tsagkaraki I; Gomes AR; Prideaux S; Chen L; Prodger C; Khera A; Gray N; Ellis L; Sangha G; Eyre TA; Moore S; Kothari J; Ramasamy K
PLoS One; 2022; 17(1):e0262388. PubMed ID: 35015781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]